PBP Stock Overview
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally.
No risks detected for PBP from our risk checks.
Notes are coming soon
Probiotec Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.23|
|52 Week High||AU$2.42|
|52 Week Low||AU$2.02|
|1 Month Change||1.36%|
|3 Month Change||3.24%|
|1 Year Change||0.45%|
|3 Year Change||-8.61%|
|5 Year Change||159.30%|
|Change since IPO||93.07%|
Recent News & Updates
|PBP||AU Pharmaceuticals||AU Market|
Return vs Industry: PBP exceeded the Australian Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: PBP underperformed the Australian Market which returned 2.2% over the past year.
|PBP Average Weekly Movement||3.9%|
|Pharmaceuticals Industry Average Movement||9.6%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.5%|
|10% least volatile stocks in AU Market||3.4%|
Stable Share Price: PBP is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PBP's weekly volatility (4%) has been stable over the past year.
About the Company
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, ointments, and suspensions; powders and powder blending; and sprays, as well as manufactures and packages finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
|PBP fundamental statistics|
Is PBP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PBP income statement (TTM)|
|Cost of Revenue||AU$125.09m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.17|
|Net Profit Margin||7.52%|
How did PBP perform over the long term?See historical performance and comparison